In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, January 07, 2019

**Test Changes** - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

**Discontinued Tests** - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.
<table>
<thead>
<tr>
<th>Test Code</th>
<th>Test Name</th>
<th>Test Name</th>
<th>Method / CPT Code</th>
<th>Specimen Req.</th>
<th>Stability</th>
<th>Scope</th>
<th>Units</th>
<th>Reference</th>
<th>Comments</th>
<th>Discontinue</th>
</tr>
</thead>
<tbody>
<tr>
<td>0088U</td>
<td>Acetonitrile Exposure Profile, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0148U</td>
<td>Acrylonitrile Exposure Profile, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0213B</td>
<td>Allopurinol and Metabolite, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0213SP</td>
<td>Allopurinol and Metabolite, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0982SP</td>
<td>Carbidopa, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52152B</td>
<td>Cimetidine Confirmation, Blood (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52152SP</td>
<td>Cimetidine Confirmation, Serum/Plasma (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52152U</td>
<td>Cimetidine Confirmation, Urine (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9542B</td>
<td>Cimetidine Screen (Add-On), Blood (Forensic) (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9542SP</td>
<td>Cimetidine Screen (Add-On), Serum/Plasma (Forensic) (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9542U</td>
<td>Cimetidine Screen (Add-On), Urine (Forensic) (CSA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1262B</td>
<td>Cimetidine, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1262SP</td>
<td>Cimetidine, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1262U</td>
<td>Cimetidine, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54228B</td>
<td>Dicyclomine Confirmation (DUID/DRE), Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54228U</td>
<td>Dicyclomine Confirmation (Qualitative) (DUID/DRE), Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52028B</td>
<td>Dicyclomine Confirmation, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5498B</td>
<td>Dicyclomine Confirmation, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52028FL</td>
<td>Dicyclomine Confirmation, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52028SP</td>
<td>Dicyclomine Confirmation, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52028TI</td>
<td>Dicyclomine Confirmation, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52028U</td>
<td>Dicyclomine Confirmation, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9151B</td>
<td>Dicyclomine Screen, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1575B</td>
<td>Dicyclomine, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1575SP</td>
<td>Dicyclomine, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1575U</td>
<td>Dicyclomine, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1902B</td>
<td>Duexis®, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1902SP</td>
<td>Duexis®, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9323SP</td>
<td>Ethane, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2055SP</td>
<td>Ethylene Glycol Overexposure Profile, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2068B</td>
<td>Famotidine, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test Code</td>
<td>Test Name</td>
<td>Test Name</td>
<td>Method / CPT Code</td>
<td>Specimen Req.</td>
<td>Stability</td>
<td>Scope</td>
<td>Units</td>
<td>Reference Comments</td>
<td>Discontinue</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>-------------------</td>
<td>---------------</td>
<td>----------</td>
<td>-------</td>
<td>-------</td>
<td>---------------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>2068SP</td>
<td>Famotidine, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2134SP</td>
<td>Formic Acid, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2134U</td>
<td>Formic Acid, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52052B</td>
<td>Guaifenesin Confirmation, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52052FL</td>
<td>Guaifenesin Confirmation, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52052SP</td>
<td>Guaifenesin Confirmation, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2185B</td>
<td>Guaifenesin, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2185SP</td>
<td>Guaifenesin, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>54260B</td>
<td>Levetiracetam Confirmation (DUID/DRE), Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>54260U</td>
<td>Levetiracetam Confirmation (Qualitative) (DUID/DRE), Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52060B</td>
<td>Levetiracetam Confirmation, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52060FL</td>
<td>Levetiracetam Confirmation, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52060SP</td>
<td>Levetiracetam Confirmation, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52060TI</td>
<td>Levetiracetam Confirmation, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52060U</td>
<td>Levetiracetam Confirmation, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2505B</td>
<td>Levetiracetam, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2505SP</td>
<td>Levetiracetam, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2504SP</td>
<td>Levodopa, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2836U</td>
<td>Methanol Exposure Profile, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2837SP</td>
<td>Methanol Poisoning Profile, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2834B</td>
<td>Methanol, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2834SP</td>
<td>Methanol, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2834U</td>
<td>Methanol, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>54276B</td>
<td>Methocarbamol Confirmation (DUID/DRE), Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52076B</td>
<td>Methocarbamol Confirmation, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52076FL</td>
<td>Methocarbamol Confirmation, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52076SP</td>
<td>Methocarbamol Confirmation, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>52076TI</td>
<td>Methocarbamol Confirmation, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2900B</td>
<td>Methocarbamol, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2900FL</td>
<td>Methocarbamol, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>2900SP</td>
<td>Methocarbamol, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Test Code</td>
<td>Test Name</td>
<td>Method / CPT Code</td>
<td>Specimen Req.</td>
<td>Stability</td>
<td>Scope</td>
<td>Units</td>
<td>Reference Comments</td>
<td>Discontinue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>-------</td>
<td>-------</td>
<td>---------------------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3063SP</td>
<td>Mycophenolic Acid and Metabolite, Serum/Plasma</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54291B</td>
<td>Olanzapine Confirmation (DUID/DRE), Blood</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54291U</td>
<td>Olanzapine Confirmation (Qualitative) (DUID/DRE), Urine</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52091B</td>
<td>Olanzapine Confirmation, Blood</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52091SP</td>
<td>Olanzapine Confirmation, Serum/Plasma</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52091U</td>
<td>Olanzapine Confirmation, Urine</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3226B</td>
<td>Olanzapine and Metabolite, Blood</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3226SP</td>
<td>Olanzapine and Metabolite, Serum/Plasma</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10198SP</td>
<td>Olanzapine and Metabolite, Serum/Plasma (CSA)</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3226FL</td>
<td>Olanzapine, Fluid</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10196SP</td>
<td>Olanzapine, Serum/Plasma (CSA)</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3226TI</td>
<td>Olanzapine, Tissue</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3932B</td>
<td>Procainamide and Metabolite, Blood</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3932SP</td>
<td>Procainamide and Metabolite, Serum/Plasma</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52107B</td>
<td>Procainamide and NAPA Confirmation, Blood</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52107FL</td>
<td>Procainamide and NAPA Confirmation, Fluid</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52107SP</td>
<td>Procainamide and NAPA Confirmation, Serum/Plasma</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52107TI</td>
<td>Procainamide and NAPA Confirmation, Tissue</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52107U</td>
<td>Procainamide and NAPA Confirmation, Urine</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52159FL</td>
<td>Ranitidine Confirmation, Fluid (CSA)</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52159SP</td>
<td>Ranitidine Confirmation, Serum/Plasma (CSA)</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52159U</td>
<td>Ranitidine Confirmation, Urine (CSA)</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9549B</td>
<td>Ranitidine Screen (Add-On), Blood (Forensic) (CSA)</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9549FL</td>
<td>Ranitidine Screen (Add-On), Fluid (Forensic) (CSA)</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9549SP</td>
<td>Ranitidine Screen (Add-On), Serum/Plasma (Forensic) (CSA)</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9549U</td>
<td>Ranitidine Screen (Add-On), Urine (Forensic) (CSA)</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4085B</td>
<td>Ranitidine, Blood</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4085SP</td>
<td>Ranitidine, Serum/Plasma</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4085U</td>
<td>Ranitidine, Urine</td>
<td>•</td>
<td>•</td>
<td>•</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test Code</td>
<td>Test Name</td>
<td>Test Name</td>
<td>Method / CPT Code</td>
<td>Specimen Req.</td>
<td>Stability</td>
<td>Scope</td>
<td>Units</td>
<td>Reference Comments</td>
<td>Discontinue</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------</td>
<td>---------------------------</td>
<td>-------------------</td>
<td>---------------</td>
<td>-----------</td>
<td>-------</td>
<td>-------</td>
<td>---------------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>4205SP</td>
<td>Sinemet®, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4211B</td>
<td>Stiripentol, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4211SP</td>
<td>Stiripentol, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3230B</td>
<td>Symbyax®, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3230SP</td>
<td>Symbyax®, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54135B</td>
<td>Xylazine Confirmation (DUID/DRE), Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54135U</td>
<td>Xylazine Confirmation (Qualitative) (DUID/DRE), Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52135B</td>
<td>Xylazine Confirmation, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52135FL</td>
<td>Xylazine Confirmation, Fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52135SP</td>
<td>Xylazine Confirmation, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52135TI</td>
<td>Xylazine Confirmation, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52135U</td>
<td>Xylazine Confirmation, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4815B</td>
<td>Xylazine, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4815SP</td>
<td>Xylazine, Serum/Plasma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4815TI</td>
<td>Xylazine, Tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4815U</td>
<td>Xylazine, Urine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Test Changes

### 0088U  Acetonitrile Exposure Profile, Urine

**Summary of Changes:**
- Specimen Requirements (Transport Temperature) were changed.
- Specimen Requirements (Special Handling) were changed.
- Specimen Requirements (Rejection Criteria) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [GC/MS (83921)]

**Specimen Requirements:**
- **Transport Temperature:** Frozen
- **Specimen Container:** Plastic container (preservative-free)
- **Light Protection:** Not Required
- **Special Handling:** Freeze immediately and ship with dry ice.
- **Rejection Criteria:** Received Room Temperature. Received Refrigerated.
- **Stability:** Room Temperature: Not Stable
  - Refrigerated: Not Stable
  - Frozen (-20 °C): 3 month(s)

**Scope of Analysis:**
- GC/MS (83921): Formic Acid, Formic Acid (Creatinine corrected)
- IC (84430): Thiocyanate, Thiocyanate (Creatinine corrected)
- Colorimetry (82570): Creatinine

### Compound Name | Units | Reference Comment
--- | --- | ---
Formic Acid | mcg/mL | In a study of 70 non-exposed individuals, the median level of formic acid in urine was 13.6 mcg/mL (range 1.0 - 95 mcg/mL). Formic acid is also a metabolite of methanol, formaldehyde, and methyl formate among others. Values may vary depending on environmental and occupational exposures, diet, nutritional condition, and pregnancy status.

Formic Acid (Creatinine corrected) | mg/g Creat | In a study of 70 non-exposed individuals, the median level of formic acid in urine was 14 mg/g creatinine with the 95th percentile at 23 mg/g creatinine (range 1.2 - 280 mg/g creatinine). Formic acid is also a metabolite of methanol, formaldehyde, and methyl formate among others. Values may vary depending on environmental and occupational exposures, diet, nutritional condition, and pregnancy status.

---

### 0148U  Acrylonitrile Exposure Profile, Urine
Test Changes

Summary of Changes: Specimen Requirements (Transport Temperature) were changed.
Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [GC/MS (83921)]

Specimen Requirements: 4 mL Urine
Transport Temperature: Frozen
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Freeze immediately and ship with dry ice.
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 3 month(s)

Scope of Analysis: GC/MS (83921): Formic Acid, Formic Acid (Creatinine corrected)
Method (CPT Code) IC (84430): Thiocyanate, Thiocyanate (Creatinine corrected)
Colorimetry (82570): Creatinine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formic Acid</td>
<td>mcg/mL</td>
<td>In a study of 70 non-exposed individuals, the median level of formic acid in urine was 13.6 mcg/mL (range 1.0 - 95 mcg/mL). Formic acid is also a metabolite of methanol, formaldehyde, and methyl formate among others. Values may vary depending on environmental and occupational exposures, diet, nutritional condition, and pregnancy status.</td>
</tr>
<tr>
<td>Formic Acid (Creatinine corrected)</td>
<td>mg/g Creat</td>
<td>In a study of 70 non-exposed individuals, the median level of formic acid in urine was 14 mg/g creatinine with the 95th percentile at 23 mg/g creatinine (range 1.2 - 280 mg/g creatinine). Formic acid is also a metabolite of methanol, formaldehyde, and methyl formate among others. Values may vary depending on environmental and occupational exposures, diet, nutritional condition, and pregnancy status.</td>
</tr>
</tbody>
</table>

0213SP  Allopurinol and Metabolite, Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
## Test Changes

**Scope of Analysis:** LC-MS/MS (80375): Oxypurinol, Allopurinol

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxypurinol</td>
<td>mcg/mL</td>
<td>Peak plasma oxypurinol concentrations after a single 300 mg oral dose of allopurinol averaged 6.5 mcg/mL at 4.5 hours. After seven daily oral doses of 300 mg allopurinol, reported peak plasma concentrations of oxypurinol averaged 12 mcg/mL.</td>
</tr>
<tr>
<td>Allopurinol</td>
<td>mcg/mL</td>
<td>Peak plasma allopurinol concentrations after a single 300 mg oral dose averaged 3 mcg/mL at 1.5 hours. After seven daily oral doses of 300 mg, reported peak plasma concentrations of allopurinol averaged 1.2 mcg/mL.</td>
</tr>
</tbody>
</table>

### 52152B  Cimetidine Confirmation, Blood (CSA)

**Summary of Changes:** Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

<table>
<thead>
<tr>
<th>Specimen Requirements:</th>
<th>1 mL Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Lavender top tube (EDTA)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
<tr>
<td>Special Handling:</td>
<td>None</td>
</tr>
<tr>
<td>Rejection Criteria:</td>
<td>None</td>
</tr>
<tr>
<td>Stability:</td>
<td>Room Temperature: 30 day(s)</td>
</tr>
<tr>
<td></td>
<td>Refrigerated: 30 day(s)</td>
</tr>
<tr>
<td></td>
<td>Frozen (-20 °C): 30 day(s)</td>
</tr>
</tbody>
</table>

**Scope of Analysis:** LC-MS/MS (80375): Cimetidine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimetidine</td>
<td>mcg/mL</td>
<td>Therapeutic range for 50% inhibition of gastric acid secretion: 0.5 - 1.0 mcg/mL plasma. The blood to plasma ratio is approximately 1.</td>
</tr>
</tbody>
</table>

### 52152SP  Cimetidine Confirmation, Serum/Plasma (CSA)

**Summary of Changes:** Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

<table>
<thead>
<tr>
<th>Specimen Requirements:</th>
<th>1 mL Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Lavender top tube (EDTA)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
<tr>
<td>Special Handling:</td>
<td>None</td>
</tr>
<tr>
<td>Rejection Criteria:</td>
<td>None</td>
</tr>
<tr>
<td>Stability:</td>
<td>Room Temperature: 30 day(s)</td>
</tr>
<tr>
<td></td>
<td>Refrigerated: 30 day(s)</td>
</tr>
<tr>
<td></td>
<td>Frozen (-20 °C): 30 day(s)</td>
</tr>
</tbody>
</table>

**Scope of Analysis:** LC-MS/MS (80375): Cimetidine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimetidine</td>
<td>mcg/mL</td>
<td>Therapeutic range for 50% inhibition of gastric acid secretion: 0.5 - 1.0 mcg/mL plasma. The blood to plasma ratio is approximately 1.</td>
</tr>
</tbody>
</table>
Test Changes

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial
using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).

Stability:
- Room Temperature: 30 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 30 day(s)

Scope of Analysis:
Method (CPT Code) LC-MS/MS (80375): Cimetidine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimetidine</td>
<td>mcg/mL</td>
<td>Therapeutic range for 50% inhibition of gastric acid secretion: 0.5 - 1.0 mcg/mL plasma.</td>
</tr>
</tbody>
</table>

52152U  Cimetidine Confirmation, Urine (CSA)

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

Stability:
- Room Temperature: 14 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 30 day(s)

Scope of Analysis:
Method (CPT Code) LC-MS/MS (80375): Cimetidine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimetidine</td>
<td>mcg/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

9542B  Cimetidine Screen (Add-On), Blood (Forensic) (CSA)
Test Changes

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80307)]

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimetidine</td>
<td>mcg/mL</td>
<td>Therapeutic range for 50% inhibition of gastric acid secretion: 0.5 - 1.0 mcg/mL plasma. The blood to plasma ratio is approximately 1.</td>
</tr>
</tbody>
</table>

9542SP  Cimetidine Screen (Add-On), Serum/Plasma (Forensic) (CSA)

Summary of Changes: Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80307)]

| Specimen Requirements: 1 mL Serum or Plasma |
| Transport Temperature: Refrigerated |
| Specimen Container: Plastic container (preservative-free) |
| Light Protection: Not Required |
| Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. |
| Rejection Criteria: Polymer gel separation tube (SST or PST). |
| Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s) |
| Scope of Analysis: Method (CPT Code) LC-MS/MS (80307): Cimetidine |
## Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimetidine</td>
<td>mcg/mL</td>
<td>Therapeutic range for 50% inhibition of gastric acid secretion: 0.5 - 1.0 mcg/mL plasma.</td>
</tr>
</tbody>
</table>

### 9542U  Cimetidine Screen (Add-On), Urine (Forensic) (CSA)

**Summary of Changes:** Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed.

<table>
<thead>
<tr>
<th>Specimen Requirements:</th>
<th>1 mL Urine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Plastic container (preservative-free)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
<tr>
<td>Special Handling:</td>
<td>None</td>
</tr>
<tr>
<td>Rejection Criteria:</td>
<td>None</td>
</tr>
<tr>
<td><strong>Stability:</strong></td>
<td>Room Temperature: 14 day(s)</td>
</tr>
<tr>
<td></td>
<td>Refrigerated: 30 day(s)</td>
</tr>
<tr>
<td></td>
<td>Frozen (-20 °C): 30 day(s)</td>
</tr>
<tr>
<td><strong>Scope of Analysis:</strong></td>
<td>LC-MS/MS (80307): Cimetidine</td>
</tr>
</tbody>
</table>

### 1262B  Cimetidine, Blood

**Summary of Changes:** Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

<table>
<thead>
<tr>
<th>Specimen Requirements:</th>
<th>1 mL Blood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Lavender top tube (EDTA)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
<tr>
<td>Special Handling:</td>
<td>None</td>
</tr>
<tr>
<td>Rejection Criteria:</td>
<td>None</td>
</tr>
<tr>
<td><strong>Stability:</strong></td>
<td>Room Temperature: 30 day(s)</td>
</tr>
<tr>
<td></td>
<td>Refrigerated: 30 day(s)</td>
</tr>
<tr>
<td></td>
<td>Frozen (-20 °C): 30 day(s)</td>
</tr>
</tbody>
</table>
### Test Changes

**Scope of Analysis:** LC-MS/MS (80375): Cimetidine  
**Method (CPT Code):**

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
</table>
| Cimetidine    | mcg/mL| Therapeutic range for 50% inhibition of gastric acid secretion: 0.5 - 1.0 mcg/mL plasma.  
The blood to plasma ratio is approximately 1. |

#### 1262SP Cimetidine, Serum/Plasma

**Summary of Changes:** Specimen Requirements were changed.  
Stability was changed.  
Reference Comment was changed.  
Methods/CPT Codes were changed [LC-MS/MS (80375)]

**Specimen Requirements:** 1 mL Serum or Plasma  
Transport Temperature: Refrigerated  
Specimen Container: Plastic container (preservative-free)  
Light Protection: Not Required  
Special Handling: Serum: Collect sample in Red top tube  
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.  
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.  
Rejection Criteria: Polymer gel separation tube (SST or PST).  
Stability: Room Temperature: 30 day(s)  
Refrigerated: 30 day(s)  
Frozen (-20 °C): 30 day(s)

**Scope of Analysis:** LC-MS/MS (80375): Cimetidine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cimetidine</td>
<td>mcg/mL</td>
<td>Therapeutic range for 50% inhibition of gastric acid secretion: 0.5 - 1.0 mcg/mL plasma.</td>
</tr>
</tbody>
</table>

#### 1262U Cimetidine, Urine

**Summary of Changes:** Specimen Requirements (Specimen Container) were changed.  
Stability was changed.  
Methods/CPT Codes were changed [LC-MS/MS (80375)]
Test Changes

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80375): Cimetidine

Summary of Changes:
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

54228B Dicyclomine Confirmation (DUID/DRE), Blood

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 7 day(s)
Scope of Analysis: LC-MS/MS (80375): Dicyclomine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dicyclomine</td>
<td>ng/mL</td>
<td>The peak plasma concentration in a single volunteer following a single oral dose of 20 mg dicyclomine was approximately 20 ng/mL at 1.5 hours. The blood to plasma ratio is unknown for this compound.</td>
</tr>
</tbody>
</table>

54228U Dicyclomine Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]
## Test Changes

### Stability:
- Room Temperature: 30 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 30 day(s)

### Scope of Analysis:
- LC-MS/MS (80375): Dicyclomine

### Compound Name | Units | Reference Comment
--- | --- | ---
Dicyclomine | ng/mL | No reference data available.

## 52028B  Dicyclomine Confirmation, Blood

### Summary of Changes:
- Specimen Requirements were changed.
- Specimen Requirements (Specimen Container) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80375)]

### Specimen Requirements:
- 1 mL Blood
- Refrigerated
- Lavender top tube (EDTA)
- Not Required
- None
- None
- Room Temperature: 30 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 7 day(s)
- LC-MS/MS (80375): Dicyclomine

### Compound Name | Units | Reference Comment
--- | --- | ---
Dicyclomine | ng/mL | The peak plasma concentration in a single volunteer following a single oral dose of 20 mg dicyclomine was approximately 20 ng/mL at 1.5 hours. The blood to plasma ratio is unknown for this compound.

## 52028FL  Dicyclomine Confirmation, Fluid

### Summary of Changes:
- Specimen Requirements (Specimen Container) were changed.
- Methods/CPT Codes were changed [LC-MS/MS (80375)]
## Test Changes

<table>
<thead>
<tr>
<th>Specimen Requirements:</th>
<th>2 mL Fluid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Plastic container (preservative-free)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
<tr>
<td>Special Handling:</td>
<td>None</td>
</tr>
<tr>
<td>Rejection Criteria:</td>
<td>None</td>
</tr>
<tr>
<td>Scope of Analysis:</td>
<td>LC-MS/MS (80375): Dicyclomine</td>
</tr>
</tbody>
</table>

### 52028SP Dicyclomine Confirmation, Serum/Plasma

<table>
<thead>
<tr>
<th>Specimen Requirements:</th>
<th>1 mL Serum or Plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transport Temperature:</td>
<td>Refrigerated</td>
</tr>
<tr>
<td>Specimen Container:</td>
<td>Plastic container (preservative-free)</td>
</tr>
<tr>
<td>Light Protection:</td>
<td>Not Required</td>
</tr>
<tr>
<td>Special Handling:</td>
<td>Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.</td>
</tr>
<tr>
<td>Rejection Criteria:</td>
<td>Polymer gel separation tube (SST or PST).</td>
</tr>
<tr>
<td>Stability:</td>
<td>Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 30 day(s)</td>
</tr>
<tr>
<td>Scope of Analysis:</td>
<td>LC-MS/MS (80375): Dicyclomine</td>
</tr>
</tbody>
</table>

### Compound Name | Units | Reference Comment
--- | --- | ---
Dicyclomine | ng/mL | The peak plasma concentration in a single volunteer following a single oral dose of 20 mg dicyclomine was approximately 20 ng/mL at 1.5 hours.

### 52028TI Dicyclomine Confirmation, Tissue

| Specimen Requirements (Specimen Container) were changed. |
| Methods/CPT Codes were changed [LC-MS/MS (80375)] |
## Test Changes

**Specimen Requirements:** 10 g Tissue  
**Transport Temperature:** Refrigerated  
**Specimen Container:** Plastic container (preservative-free)  
**Light Protection:** Not Required  
**Special Handling:** None  
**Rejection Criteria:** None  
**Scope of Analysis:** LC-MS/MS (80375): Dicyclomine  
**Method (CPT Code)**

<table>
<thead>
<tr>
<th>Code</th>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>52028U</td>
<td>Dicyclomine, Urine</td>
<td>ng/mL</td>
<td>The peak plasma concentration in a single volunteer following a single oral dose of 20 mg dicyclomine was approximately 20 ng/mL at 1.5 hours. The blood to plasma ratio is unknown for this compound.</td>
</tr>
<tr>
<td>1575B</td>
<td>Dicyclomine, Blood</td>
<td>ng/mL</td>
<td></td>
</tr>
</tbody>
</table>
Test Changes

1575SP  Dicyclomine, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial
using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 7 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80375): Dicyclomine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dicyclomine</td>
<td>ng/mL</td>
<td>The peak plasma concentration in a single volunteer following a single oral dose of 20 mg dicyclomine was approximately 20 ng/mL at 1.5 hours.</td>
</tr>
</tbody>
</table>

1575U  Dicyclomine, Urine

Summary of Changes: Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80375): Dicyclomine

2055SP  Ethylene Glycol Overexposure Profile, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Reference Comment was changed.
Methods/CPT Codes were changed [GC/MS (83921)]
Test Changes

Specimen Requirements: 5 mL Serum or Plasma
Transport Temperature: Frozen
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Green top tube (Sodium Heparin)
Promptly centrifuge with refrigeration and separate Serum or Plasma into chilled plastic screw capped vial using approved guidelines. Freeze immediately and ship with dry ice.
Ascorbic acid at very high concentration (exceeding 51 mc mol/mL plasma) can interfere. It is recommended that patients refrain from taking excessive amounts of vitamin C or vitamin C rich food for at least 48 hours prior to collection.
Rejection Criteria: Received Room Temperature. Received Refrigerated. Gray top tube (Sodium Fluoride / Potassium Oxalate). Polymer gel separation tube (SST or PST).
Scope of Analysis:
Method (CPT Code)
EZA (83945): Oxalate
GC (82693): Ethylene Glycol
GC/MS (83921): Formic Acid

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formic Acid</td>
<td>mcg/mL</td>
<td>Normal plasma formic acid range is 1 - 9 mcg/mL (in pregnant women, 0.5 - 44 mcg/mL). Formic acid is also a metabolite of methanol, formaldehyde, and methyl formate among others. Values may vary depending on environmental and occupational exposures, diet, nutritional condition, and pregnancy status.</td>
</tr>
</tbody>
</table>

2068B Famotidine, Blood

Summary of Changes: Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 7 day(s)
Scope of Analysis: LC-MS/MS (80375): Famotidine
Method (CPT Code)
### Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Famotidine</td>
<td>ng/mL</td>
<td>Therapeutic range for gastric pH of 4.0: 18 +/- 11 ng/mL</td>
</tr>
</tbody>
</table>

#### 2134SP Formic Acid, Serum/Plasma

**Summary of Changes:**
- Specimen Requirements were changed.
- Specimen Requirements (Special Handling) were changed.
- Specimen Requirements (Rejection Criteria) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [GC/MS (83921)]

**Specimen Requirements:**
- 2 mL Serum or Plasma

**Transport Temperature:**
- Refrigerated

**Specimen Container:**
- Plastic container (preservative-free)

**Light Protection:**
- Not Required

**Special Handling:**
- Serum: Collect sample in Red top tube
- Plasma: Collect sample in Gray top tube (Sodium Fluoride / Potassium Oxalate) or Green top tube (Sodium Heparin).
- Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.

**Rejection Criteria:**
- Polymer gel separation tube (SST or PST).

**Stability:**
- Room Temperature: 7 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 3 month(s)

**Scope of Analysis:**
- GC/MS (83921): Formic Acid

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formic Acid</td>
<td>mcg/mL</td>
<td>Normal plasma formic acid range is 1 - 9 mcg/mL (in pregnant women, 0.5 - 44 mcg/mL). Formic acid is also a metabolite of methanol, formaldehyde, and methyl formate among others. Values may vary depending on environmental and occupational exposures, diet, nutritional condition, and pregnancy status.</td>
</tr>
</tbody>
</table>

#### 2134U Formic Acid, Urine

**Summary of Changes:**
- Specimen Requirements (Transport Temperature) were changed.
- Specimen Requirements (Special Handling) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [GC/MS (83921)]
Test Changes

Specimen Requirements: 3 mL Urine
Transport Temperature: Frozen
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Freeze immediately and ship with dry ice.
Rejection Criteria: Received Room Temperature. Received Refrigerated.
Stability: Room Temperature: Not Stable
Refrigerated: Not Stable
Frozen (-20 °C): 3 month(s)
Scope of Analysis:
Method (CPT Code) GC/MS (83921): Formic Acid, Formic Acid (Creatinine corrected)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formic Acid</td>
<td>mcg/mL</td>
<td>In a study of 70 non-exposed individuals, the median level of formic acid in urine was 13.6 mcg/mL (range 1.0 - 95 mcg/mL). Formic acid is also a metabolite of methanol, formaldehyde, and methyl formate among others. Values may vary depending on environmental and occupational exposures, diet, nutritional condition, and pregnancy status.</td>
</tr>
<tr>
<td>Formic Acid (Creatinine corrected)</td>
<td>mg/g Creat</td>
<td>In a study of 70 non-exposed individuals, the median level of formic acid in urine was 14 mg/g creatinine with the 95th percentile at 23 mg/g creatinine (range 1.2 - 280 mg/g creatinine). Formic acid is also a metabolite of methanol, formaldehyde, and methyl formate among others. Values may vary depending on environmental and occupational exposures, diet, nutritional condition, and pregnancy status.</td>
</tr>
</tbody>
</table>

52052B Guaifenesin Confirmation, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)
Test Changes

Scope of Analysis: LC-MS/MS (80375): Guaifenesin
Method (CPT Code)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guaifenesin</td>
<td>mcg/mL</td>
<td>Following a single 600 mg oral dose: Peak blood concentrations averaged 1.4 mcg/mL at 15 minutes post dose. Half-life in plasma: 3 hours.</td>
</tr>
</tbody>
</table>

52052FL  Guaifenesin Confirmation, Fluid

Summary of Changes: Specimen Requirements were changed.

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None

52052SP  Guaifenesin Confirmation, Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.

Stability:
Room Temperature: 2 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)

Scope of Analysis: LC-MS/MS (80375): Guaifenesin
Method (CPT Code)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guaifenesin</td>
<td>mcg/mL</td>
<td>Following a single 600 mg oral dose: Peak blood concentrations averaged 1.4 mcg/mL at 15 minutes post dose. Half-life in plasma: 3 hours. The blood to plasma ratio is unknown for this compound.</td>
</tr>
</tbody>
</table>

2185B  Guaifenesin, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)
Scope of Analysis: LC-MS/MS (80375): Guaifenesin

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guaifenesin</td>
<td>mcg/mL</td>
<td>Following a single 600 mg oral dose: Peak blood concentrations averaged 1.4 mcg/mL at 15 minutes post dose. Half-life in plasma: 3 hours.</td>
</tr>
</tbody>
</table>

2185SP  Guaifenesin, Serum/Plasma

Summary of Changes: Stability was changed. Reference Comment was changed.

| Stability: Room Temperature: 2 day(s) | Refrigerated: 30 day(s) | Frozen (-20 °C): 24 month(s) | Scope of Analysis: LC-MS/MS (80375): Guaifenesin |

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guaifenesin</td>
<td>mcg/mL</td>
<td>Following a single 600 mg oral dose: Peak blood concentrations averaged 1.4 mcg/mL at 15 minutes post dose. Half-life in plasma: 3 hours. The blood to plasma ratio is unknown for this compound.</td>
</tr>
</tbody>
</table>

54260B  Leviracetam Confirmation (DUID/DRE), Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80177)]
Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80177): Levetiracetam

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam</td>
<td>mcg/mL</td>
<td>Steady-state trough plasma concentrations following doses of 500 to 3000 mg/day: 1.1 to 33 mcg/mL. The blood to plasma ratio is approximately 0.9. This test is not chiral specific. Levetiracetam cannot be distinguished from its inactive isomer etiracetam.</td>
</tr>
</tbody>
</table>

54260U Levetiracetam Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes:
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80177)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80177): Levetiracetam

52060B Levetiracetam Confirmation, Blood

Summary of Changes:
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80177)]
Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.

Stability:
- Room Temperature: 2 day(s)
- Refrigerated: 7 day(s)
- Frozen (-20 °C): 30 day(s)

Scope of Analysis:
LC-MS/MS (80177): Levetiracetam

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam</td>
<td>mcg/mL</td>
<td>Steady-state trough plasma concentrations following doses of 500 to 3000 mg/day: 1.1 to 33 mcg/mL. The blood to plasma ratio is approximately 0.9. This test is not chiral specific. Levetiracetam cannot be distinguished from its inactive isomer etiracetam.</td>
</tr>
</tbody>
</table>

52060FL Levetiracetam Confirmation, Fluid

Summary of Changes: Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80177)]

Scope of Analysis:
- Method (CPT Code): LC-MS/MS (80177): Levetiracetam

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam</td>
<td>mcg/mL</td>
<td>This test is not chiral specific. Levetiracetam cannot be distinguished from its inactive isomer etiracetam.</td>
</tr>
</tbody>
</table>

52060SP Levetiracetam Confirmation, Serum/Plasma

Summary of Changes: Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80177)]

Scope of Analysis:
- Method (CPT Code): LC-MS/MS (80177): Levetiracetam

Stability:
- Room Temperature: 30 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 10 month(s)
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam</td>
<td>mcg/mL</td>
<td>Steady-state trough plasma concentrations following doses of 500 to 3000 mg/day: 1.1 to 33 mcg/mL. This test is not chiral specific. Levetiracetam cannot be distinguished from its inactive isomer etiracetam.</td>
</tr>
</tbody>
</table>

52060TI  Levetiracetam Confirmation, Tissue

Summary of Changes: Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80177)]

Scope of Analysis: LC-MS/MS (80177): Levetiracetam

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam</td>
<td>mcg/g</td>
<td>This test is not chiral specific. Levetiracetam cannot be distinguished from its inactive isomer etiracetam.</td>
</tr>
</tbody>
</table>

52060U  Levetiracetam Confirmation, Urine

Summary of Changes: Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80177)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
            Refrigerated: 30 day(s)
            Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80177): Levetiracetam

2505B  Levetiracetam, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80177)]
Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80177): Levetiracetam

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam</td>
<td>mcg/mL</td>
<td>Steady-state trough plasma concentrations following doses of 500 to 3000 mg/day: 1.1 to 33 mcg/mL. The blood to plasma ratio is approximately 0.9. This test is not chiral specific. Levetiracetam cannot be distinguished from its inactive isomer etiracetam.</td>
</tr>
</tbody>
</table>

2505SP Levetiracetam, Serum/Plasma
Summary of Changes: Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80177)]
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 10 month(s)
Scope of Analysis: LC-MS/MS (80177): Levetiracetam

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam</td>
<td>mcg/mL</td>
<td>Steady-state trough plasma concentrations following doses of 500 to 3000 mg/day: 1.1 to 33 mcg/mL. This test is not chiral specific. Levetiracetam cannot be distinguished from its inactive isomer etiracetam.</td>
</tr>
</tbody>
</table>

2504SP Levodopa, Serum/Plasma
Summary of Changes: Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed []
Test Changes

Stability:
- Room Temperature: Not Stable
- Refrigerated: Not Stable
- Frozen (-20 °C): 6 day(s)
- Frozen (-70 °C): 30 day(s)

Scope of Analysis:
- LC-MS/MS (80375): Levodopa

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levodopa</td>
<td>mcg/mL</td>
<td>The target plasma concentration of levodopa in Parkinsonian patients is 2 +/- 0.5 mcg/mL. The average peak plasma levodopa concentration following a single oral dose of Sinemet® containing 200 mg levodopa was 1.2 mcg/mL at 0.5 hours for normal release and 3.3 mcg/mL at 2 hours for controlled release. At steady-state, the average trough plasma levodopa concentration following oral Sinemet® containing 200 mg levodopa was 0.07 mcg/mL for normal release and 0.16 mcg/mL for controlled release.</td>
</tr>
</tbody>
</table>

2836U     Methanol Exposure Profile, Urine

Summary of Changes:
- Specimen Requirements (Special Handling) were changed.
- Specimen Requirements (Rejection Criteria) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [GC/MS (83921)]

<table>
<thead>
<tr>
<th>Specimen Requirements</th>
<th>Transport Temperature</th>
<th>Specimen Container</th>
<th>Light Protection</th>
<th>Special Handling</th>
<th>Rejection Criteria</th>
<th>Stability</th>
<th>Scope of Analysis</th>
<th>Method (CPT Code)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 mL Urine</td>
<td>Frozen</td>
<td>Plastic container</td>
<td>Not Required</td>
<td>Freeze immediately and ship with dry ice.</td>
<td>Received Room Temperature. Received Refrigerated.</td>
<td>Room Temperature: Not Stable Refrigerated: Not Stable Frozen (-20 °C): 3 month(s)</td>
<td>Colorimetry (82570): Creatinine</td>
<td>GC/MS (83921): Formic Acid, Formic Acid (Creatinine corrected) Headspace GC (80320): Methanol</td>
</tr>
</tbody>
</table>
## Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formic Acid</td>
<td>mcg/mL</td>
<td>In a study of 70 non-exposed individuals, the median level of formic acid in urine was 13.6 mcg/mL (range 1.0 - 95 mcg/mL). Formic acid is also a metabolite of methanol, formaldehyde, and methyl formate among others. Values may vary depending on environmental and occupational exposures, diet, nutritional condition, and pregnancy status.</td>
</tr>
<tr>
<td>Formic Acid (Creatinine corrected)</td>
<td>mg/g Creat</td>
<td>In a study of 70 non-exposed individuals, the median level of formic acid in urine was 14 mg/g creatinine with the 95th percentile at 23 mg/g creatinine (range 1.2 - 280 mg/g creatinine). Formic acid is also a metabolite of methanol, formaldehyde, and methyl formate among others. Values may vary depending on environmental and occupational exposures, diet, nutritional condition, and pregnancy status.</td>
</tr>
</tbody>
</table>
Test Changes

54276B  Methocarbamol Confirmation (DUID/DRE), Blood

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80369)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80369): Methocarbamol

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methocarbamol</td>
<td>mcg/mL</td>
<td>Following a single oral 1.5 g dose, peak plasma concentrations of methocarbamol averaged 23 mcg/mL at 1.1 hours and declined with a half-life of 1.3 hours. The blood to plasma ratio is not known for this compound.</td>
</tr>
</tbody>
</table>

52076B  Methocarbamol Confirmation, Blood

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80369)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80369): Methocarbamol
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methocarbamol</td>
<td>mcg/mL</td>
<td>Following a single oral 1.5 g dose, peak plasma concentrations of methocarbamol averaged 23 mcg/mL at 1.1 hours and declined with a half-life of 1.3 hours. The blood to plasma ratio is not known for this compound.</td>
</tr>
</tbody>
</table>

**52076FL  Methocarbamol Confirmation, Fluid**

Summary of Changes:
Specimen Requirements were changed.
Methods/CPT Codes were changed [LC-MS/MS (80369)]

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: LC-MS/MS (80369): Methocarbamol

**52076SP  Methocarbamol Confirmation, Serum/Plasma**

Summary of Changes:
Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80369)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80369): Methocarbamol
## Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methocarbamol</td>
<td>mcg/mL</td>
<td>Following a single oral 1.5 g dose, peak plasma concentrations of methocarbamol averaged 23 mcg/mL at 1.1 hours and declined with a half-life of 1.3 hours.</td>
</tr>
</tbody>
</table>

### 52076TI  Methocarbamol Confirmation, Tissue

**Summary of Changes:** Methods/CPT Codes were changed [LC-MS/MS (80369)]

**Scope of Analysis:** LC-MS/MS (80369): Methocarbamol

### 2900B  Methocarbamol, Blood

**Summary of Changes:** Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80369)]

**Specimen Requirements:** 1 mL Blood

**Transport Temperature:** Refrigerated

**Specimen Container:** Lavender top tube (EDTA)

**Light Protection:** Not Required

**Special Handling:** None

**Rejection Criteria:** None

**Stability:**
- Room Temperature: 30 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 30 day(s)

**Scope of Analysis:** LC-MS/MS (80369): Methocarbamol

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methocarbamol</td>
<td>mcg/mL</td>
<td>Following a single oral 1.5 g dose, peak plasma concentrations of methocarbamol averaged 23 mcg/mL at 1.1 hours and declined with a half-life of 1.3 hours. The blood to plasma ratio is not known for this compound.</td>
</tr>
</tbody>
</table>

### 2900FL  Methocarbamol, Fluid

**Summary of Changes:** Specimen Requirements were changed. Methods/CPT Codes were changed [LC-MS/MS (80369)]
Test Changes

Specimen Requirements: 2 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: LC-MS/MS (80369): Methocarbamol

2900SP  Methocarbamol, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80369)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial
using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80369): Methocarbamol

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methocarbamol</td>
<td>mcg/mL</td>
<td>Following a single oral 1.5 g dose, peak plasma concentrations of methocarbamol averaged 23 mcg/mL at 1.1 hours and declined with a half-life of 1.3 hours.</td>
</tr>
</tbody>
</table>

3063SP  Mycophenolic Acid and Metabolite, Serum/Plasma

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Scope of Analysis was changed.
Order of Reporting was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80180)]
Test Changes

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80180): Mycophenolic Acid, Mycophenolic Acid Glucuronide
Method (CPT Code)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mycophenolic Acid</td>
<td>mcg/mL</td>
<td>Suggested therapeutic trough plasma concentration in low to intermediate immunologic risk: 1.5 - 3.0 mcg/mL. Trough plasma concentrations of greater than 15 mcg/mL have not been correlated with an increase in MPA toxicity. The blood to plasma ratio is approximately 0.6.</td>
</tr>
<tr>
<td>Mycophenolic Acid Glucuronide</td>
<td>mcg/mL</td>
<td>MPAG/MPA ratios in stem cell transplant recipients pretreated with three 15 mg/kg infusions or two 1 g oral doses of mycophenolate mofetil averaged 35 in pediatric patients and 50 in adults.</td>
</tr>
</tbody>
</table>

54291B  Olanzapine Confirmation (DUID/DRE), Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80342)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 1 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 7 day(s)
Test Changes

Scope of Analysis: LC-MS/MS (80342): Olanzapine
Method (CPT Code)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olanzapine</td>
<td>ng/mL</td>
<td>Recommended antipsychotic range in adults: 20-80 ng/mL plasma. The blood to plasma ratio of olanzapine is approximately 0.6.</td>
</tr>
</tbody>
</table>

54291U  Olanzapine Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Specimen Requirements were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80342)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
   Light Protection: Not Required
   Special Handling: None
   Rejection Criteria: Received Room Temperature.
   Stability: Room Temperature: 2 day(s)
   Refrigerated: 30 day(s)
   Frozen (-20 °C): 30 day(s)

Scope of Analysis: LC-MS/MS (80342): Olanzapine

52091B  Olanzapine Confirmation, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80342)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
   Light Protection: Not Required
   Special Handling: None
   Rejection Criteria: Received Room Temperature.
   Stability: Room Temperature: 1 day(s)
   Refrigerated: 7 day(s)
   Frozen (-20 °C): 7 day(s)
## Test Changes

**Scope of Analysis:** LC-MS/MS (80342): Olanzapine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olanzapine</td>
<td>ng/mL</td>
<td>Recommended antipsychotic range in adults: 20-80 ng/mL plasma. The blood to plasma ratio of olanzapine is approximately 0.6.</td>
</tr>
</tbody>
</table>

### 52091SP  Olanzapine Confirmation, Serum/Plasma

**Summary of Changes:** Specimen Requirements were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80342)]

**Specimen Requirements:** 1 mL Serum or Plasma

**Transport Temperature:** Refrigerated

**Specimen Container:** Plastic container (preservative-free)

**Light Protection:** Not Required

**Special Handling:** Serum: Collect sample in Red top tube. Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.

**Rejection Criteria:** Polymer gel separation tube (SST or PST).

**Stability:** Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 2 month(s)

**Scope of Analysis:** LC-MS/MS (80342): Olanzapine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olanzapine</td>
<td>ng/mL</td>
<td>Recommended antipsychotic range in adults: 20-80 ng/mL plasma.</td>
</tr>
</tbody>
</table>

### 52091U  Olanzapine Confirmation, Urine

**Summary of Changes:** Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80342)]
Test Changes

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
            Refrigerated: 30 day(s)
            Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80342): Olanzapine
Method (CPT Code)

3226B Olanzapine and Metabolite, Blood

Summary of Changes: Test Name was changed.
Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Scope of Analysis was changed.
N-desmethylolanzapine was added.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80342)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Gray top tube (Sodium Fluoride / Potassium Oxalate)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 1 day(s)
            Refrigerated: 7 day(s)
            Frozen (-20 °C): 7 day(s)
Scope of Analysis: LC-MS/MS (80342): N-desmethylolanzapine, Olanzapine
Method (CPT Code)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-desmethylolanzapine</td>
<td>ng/mL</td>
<td>Schizophrenic patients stabilized with olanzapine at an average daily dose of 14 mg had steady-state desmethylolanzapine plasma concentrations averaging 6.9 +/- 4.7 ng/mL. The blood to plasma ratio is not known for this compound.</td>
</tr>
</tbody>
</table>
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olanzapine</td>
<td>ng/mL</td>
<td>Recommended antipsychotic range in adults: 20-80 ng/mL plasma. The blood to plasma ratio of olanzapine is approximately 0.6.</td>
</tr>
</tbody>
</table>

10198SP  Olanzapine and Metabolite, Serum/Plasma (CSA)

Summary of Changes: Specimen Requirements (Transport Temperature) were changed. Stability was changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)

3226SP  Olanzapine and Metabolite, Serum/Plasma

Summary of Changes: Test Name was changed. Specimen Requirements were changed. Stability was changed. Scope of Analysis was changed. N-desmethylolanzapine was added. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80342)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 7 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Test Changes

Scope of Analysis: LC-MS/MS (80342): N-desmethylolanzapine, Olanzapine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-desmethylolanzapine</td>
<td>ng/mL</td>
<td>Schizophrenic patients stabilized with olanzapine at an average daily dose of 14 mg had steady-state desmethylolanzapine plasma concentrations averaging 6.9 +/- 4.7 ng/mL.</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>ng/mL</td>
<td>Recommended antipsychotic range in adults: 20-80 ng/mL plasma.</td>
</tr>
</tbody>
</table>

3226FL Olanzapine, Fluid

Summary of Changes: Specimen Requirements (Transport Temperature) were changed. Methods/CPT Codes were changed [LC-MS/MS (80342)]

Specimen Requirements: 3 mL Fluid
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: LC-MS/MS (80342): Olanzapine

10196SP Olanzapine, Serum/Plasma (CSA)

Summary of Changes: Specimen Requirements (Transport Temperature) were changed. Stability was changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 2 month(s)

3226TI Olanzapine, Tissue
Test Changes

Summary of Changes: Specimen Requirements (Transport Temperature) were changed. Methods/CPT Codes were changed.

Specimen Requirements: 10 g Tissue
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: LC-MS/MS (80342): Olanzapine

Method (CPT Code)

3932B  Procainamide and Metabolite, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80192)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 14 day(s)
Frozen (-20 °C): 14 day(s)
Scope of Analysis: LC-MS/MS (80192): Procainamide, N-Acetylprocainamide

Method (CPT Code)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procainamide</td>
<td>mcg/mL</td>
<td>The normal therapeutic range for procainamide is 3 to 10 mcg/mL plasma, but approximately 14 mcg/mL may be required for recurrent ventricular tachyarrhythmias. The blood to plasma ratio is not known for this compound.</td>
</tr>
<tr>
<td>N-Acetylprocainamide</td>
<td>mcg/mL</td>
<td>The normal therapeutic range for NAPA is 10 to 20 mcg/mL plasma. The blood to plasma ratio is not known for this compound.</td>
</tr>
</tbody>
</table>

3932SP  Procainamide and Metabolite, Serum/Plasma
Test Updates

Test Changes

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Special Handling) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80192)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80192): Procainamide, N-Acetylprocainamide

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procainamide</td>
<td>mcg/mL</td>
<td>The normal therapeutic range for procainamide is 3 to 10 mcg/mL plasma, but approximately 14 mcg/mL may be required for recurrent ventricular tachyarrhythmias.</td>
</tr>
<tr>
<td>N-Acetylprocainamide</td>
<td>mcg/mL</td>
<td>The normal therapeutic range for NAPA is 10 to 20 mcg/mL plasma.</td>
</tr>
</tbody>
</table>

52107B  Procainamide and NAPA Confirmation, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Methods/CPT Codes were changed [LC-MS/MS (80192)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Test Changes

Scope of Analysis: LC-MS/MS (80192): Procainamide, N-Acetylprocainamide

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procainamide</td>
<td>mcg/mL</td>
<td>The normal therapeutic range for procainamide is 3 to 10 mcg/mL plasma, but approximately 14 mcg/mL may be required for recurrent ventricular tachyarrhythmias. The blood to plasma ratio is not known for this compound.</td>
</tr>
<tr>
<td>N-Acetylprocainamide</td>
<td>mcg/mL</td>
<td>The normal therapeutic range for NAPA is 10 to 20 mcg/mL plasma. The blood to plasma ratio is not known for this compound.</td>
</tr>
</tbody>
</table>

52107SP  Procainamide and NAPA Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements were changed. Specimen Requirements (Special Handling) were changed. Specimen Requirements (Rejection Criteria) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80192)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Received Room Temperature. Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 2 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80192): Procainamide, N-Acetylprocainamide
Method (CPT Code) LC-MS/MS (80192): Procainamide, N-Acetylprocainamide

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procainamide</td>
<td>mcg/mL</td>
<td>The normal therapeutic range for procainamide is 3 to 10 mcg/mL plasma, but approximately 14 mcg/mL may be required for recurrent ventricular tachyarrhythmias.</td>
</tr>
</tbody>
</table>
## Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-Acetylprocainamide</td>
<td>mcg/mL</td>
<td>The normal therapeutic range for NAPA is 10 to 20 mcg/mL plasma.</td>
</tr>
</tbody>
</table>

### 52107U  Procainamide and NAPA Confirmation, Urine

Summary of Changes:
- Specimen Requirements were changed.
- Stability was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80192)]

Specimen Requirements:
- 1 mL Urine
- Transport Temperature: Refrigerated
- Specimen Container: Plastic container (preservative-free)
- Light Protection: Not Required
- Special Handling: None
- Rejection Criteria: None
- Stability:
  - Room Temperature: 14 day(s)
  - Refrigerated: 30 day(s)
  - Frozen (-20 °C): 30 day(s)
- Scope of Analysis:
  - LC-MS/MS (80192): Procainamide, N-Acetylprocainamide

### 52159FL  Ranitidine Confirmation, Fluid (CSA)

Summary of Changes:
- Specimen Requirements were changed.
- Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements:
- 2 mL Fluid
- Transport Temperature: Refrigerated
- Specimen Container: Plastic container (preservative-free)
- Light Protection: Not Required
- Special Handling: None
- Rejection Criteria: None
- Scope of Analysis:
  - LC-MS/MS (80375): Ranitidine

### 52159SP  Ranitidine Confirmation, Serum/Plasma (CSA)

Summary of Changes:
- Specimen Requirements were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80375)]
Test Changes

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial
using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80375): Ranitidine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranitidine</td>
<td>ng/mL</td>
<td>Following the oral administration of 150 mg, the reported mean peak plasma concentrations ranged from 440 - 530 ng/mL at 2 to 3 hours. With chronic administration of 150 mg twice daily, the reported trough serum concentrations were approximately 55 ng/mL. IV administration of 1 mg/kg was reported to produce mean concentrations of 3500 ng/mL at 0.5 hours, 200 ng/mL at 2 hours and 100 ng/mL at 4 hours.</td>
</tr>
</tbody>
</table>

52159U Ranitidine Confirmation, Urine (CSA)

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80375): Ranitidine
Method (CPT Code)
## Test Changes

### 9549B  Ranitidine Screen (Add-On), Blood (Forensic) (CSA)

| Specimen Requirements: | 2 mL Blood |
| Transport Temperature: | Refrigerated |
| Specimen Container: | Lavender top tube (EDTA) |
| Light Protection: | Not Required |
| Special Handling: | None |
| Rejection Criteria: | Received Room Temperature. |
| Stability: | Room Temperature: 1 day(s) |
| | Refrigerated: 7 day(s) |
| | Frozen (-20 °C): 30 day(s) |

**Scope of Analysis:**
- LC-MS/MS (80307): Ranitidine

### 9549FL  Ranitidine Screen (Add-On), Fluid (Forensic) (CSA)

| Specimen Requirements: | 4 mL Fluid |
| Transport Temperature: | Refrigerated |
| Specimen Container: | Plastic container (preservative-free) |
| Light Protection: | Not Required |
| Special Handling: | None |
| Rejection Criteria: | None |

**Scope of Analysis:**
- LC-MS/MS (80307): Ranitidine

### 9549SP  Ranitidine Screen (Add-On), Serum/Plasma (Forensic) (CSA)

| Specimen Requirements: | Specimen Requirements were changed. |
| Stability was changed. |
| Reference Comment was changed. |
| Methods/CPT Codes were changed |
Test Changes

Specimen Requirements: 2 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80307): Ranitidine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranitidine</td>
<td>ng/mL</td>
<td>Following the oral administration of 150 mg, the reported mean peak plasma concentrations ranged from 440 - 530 ng/mL at 2 to 3 hours. With chronic administration of 150 mg twice daily, the reported trough serum concentrations were approximately 55 ng/mL. IV administration of 1 mg/kg was reported to produce mean concentrations of 3500 ng/mL at 0.5 hours, 200 ng/mL at 2 hours and 100 ng/mL at 4 hours.</td>
</tr>
</tbody>
</table>

9549U Ranitidine Screen (Add-On), Urine (Forensic) (CSA)

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Methods/CPT Codes were changed [LC-MS/MS (80307)]

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 7 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80307): Ranitidine
Method (CPT Code)
## Test Changes

**4085B  Ranitidine, Blood**

| Summary of Changes: | Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)] |

| Specimen Requirements: | 1 mL Blood |
| Transport Temperature: | Refrigerated |
| Specimen Container: | Lavender top tube (EDTA) |
| Light Protection: | Not Required |
| Special Handling: | None |
| Rejection Criteria: | Received Room Temperature. |
| Stability: | Room Temperature: 1 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 30 day(s) |
| Scope of Analysis: | LC-MS/MS (80375): Ranitidine |

**4085SP  Ranitidine, Serum/Plasma**

| Summary of Changes: | Specimen Requirements were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)] |

| Specimen Requirements: | 1 mL Serum or Plasma |
| Transport Temperature: | Refrigerated |
| Specimen Container: | Plastic container (preservative-free) |
| Light Protection: | Not Required |
| Special Handling: | Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. |
| Rejection Criteria: | Polymer gel separation tube (SST or PST). |
| Stability: | Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s) |
| Scope of Analysis: | LC-MS/MS (80375): Ranitidine |

**4085U  Ranitidine, Urine**

| Summary of Changes: | Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Stability was changed. Methods/CPT Codes were changed [LC-MS/MS (80375)] |

| Specimen Requirements: | 1 mL Blood |
| Transport Temperature: | Refrigerated |
| Specimen Container: | None |
| Light Protection: | Not Required |
| Special Handling: | None |
| Rejection Criteria: | None |
| Stability: | Room Temperature: 1 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 30 day(s) |
| Scope of Analysis: | LC-MS/MS (80375): Ranitidine |
Test Changes

Specimen Requirements: 1 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 7 day(s)
            Refrigerated: 30 day(s)
            Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80375): Ranitidine

4205SP  Sinemet®, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
                    Stability was changed.
                    Reference Comment was changed.
                    Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Frozen
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
                 Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
                 Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial
                 using approved guidelines. Flash freeze immediately with dry ice.
Rejection Criteria: Received Room Temperature. Received Refrigerated. Polymer gel separation tube
                    (SST or PST).
Stability: Room Temperature: Not Stable
           Refrigerated: Not Stable
           Frozen (-20 °C): 6 day(s)
           Frozen (-70 °C): 30 day(s)

Sample must be flash frozen and shipped with dry ice. Frozen -20 C is stable up to 6
days following flash freeze.
Scope of Analysis: LC-MS/MS (80375): Levodopa, Carbidopa
Method (CPT Code)
Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levodopa</td>
<td>mcg/mL</td>
<td>The target plasma concentration of levodopa in Parkinsonian patients is 2 +/- 0.5 mcg/mL. The average peak plasma levodopa concentration following a single oral dose of Sinemet® containing 200 mg levodopa was 1.2 mcg/mL at 0.5 hours for normal release and 3.3 mcg/mL at 2 hours for controlled release. At steady-state, the average trough plasma levodopa concentration following oral Sinemet® containing 200 mg levodopa was 0.07 mcg/mL for normal release and 0.16 mcg/mL for controlled release.</td>
</tr>
<tr>
<td>Carbidopa</td>
<td>mcg/mL</td>
<td>Following a single oral dose of 250 mg levodopa and 25 mg carbidopa, peak plasma concentrations of carbidopa averaged 0.11 mcg/mL at 2.9 hours post dose. Carbidopa concentrations can decrease rapidly after collection unless flash frozen with dry ice.</td>
</tr>
</tbody>
</table>

4211B  Stiripentol, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed. Stability was changed. Reference Comment was changed. Methods/CPT Codes were changed [LC-MS/MS (80339)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80339): Stiripentol
Method (CPT Code)
### Test Changes

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stiripentol</td>
<td>mcg/mL</td>
<td>A dosing rate increase from 600 to 1200 mg/day resulted in a 253% rise in serum steady-state concentration from 0.32 +/- 0.21 to 1.13 +/- 0.54 mcg/mL. Increasing the dose from 1200 to 2400 mg/day resulted in a 397% rise in serum steady-state concentration to 5.62 +/- 3.03 mcg/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.</td>
</tr>
</tbody>
</table>

#### 4211SP  Stiripentol, Serum/Plasma

**Summary of Changes:**
- Specimen Requirements (Specimen Container) were changed.
- Specimen Requirements (Special Handling) were changed.
- Stability was changed.
- Reference Comment was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80339)]

**Specimen Requirements:**
- Transport Temperature: Refrigerated
- Specimen Container: Plastic container (preservative-free)
- Light Protection: Not Required
- Special Handling: Serum: Collect sample in Red top tube
  - Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
  - Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
- Rejection Criteria: Polymer gel separation tube (SST or PST).
- Stability: Room Temperature: 30 day(s)
  - Refrigerated: 30 day(s)
  - Frozen (-20 °C): 30 day(s)

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stiripentol</td>
<td>mcg/mL</td>
<td>A dosing rate increase from 600 to 1200 mg/day resulted in a 253% rise in serum steady-state concentration from 0.32 +/- 0.21 to 1.13 +/- 0.54 mcg/mL. Increasing the dose from 1200 to 2400 mg/day resulted in a 397% rise in serum steady-state concentration to 5.62 +/- 3.03 mcg/mL.</td>
</tr>
</tbody>
</table>

#### 54135B  Xylazine Confirmation (DUID/DRE), Blood

A dosing rate increase from 600 to 1200 mg/day resulted in a 253% rise in serum steady-state concentration from 0.32 +/- 0.21 to 1.13 +/- 0.54 mcg/mL. Increasing the dose from 1200 to 2400 mg/day resulted in a 397% rise in serum steady-state concentration to 5.62 +/- 3.03 mcg/mL.
Test Changes

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 7 day(s)
Scope of Analysis: LC-MS/MS (80375): Xylazine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylazine</td>
<td>ng/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

54135U  Xylazine Confirmation (Qualitative) (DUID/DRE), Urine

Summary of Changes: Stability was changed.
Reference Comment was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80375): Xylazine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylazine</td>
<td>ng/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

52135B  Xylazine Confirmation, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]
Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 7 day(s)
Scope of Analysis: LC-MS/MS (80375): Xylazine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylazine</td>
<td>ng/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

52135FL  Xylazine Confirmation, Fluid

Summary of Changes: Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylazine</td>
<td>ng/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

52135SP  Xylazine Confirmation, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Test Changes

Stability:
- Room Temperature: 30 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 30 day(s)

Scope of Analysis:
- LC-MS/MS (80375): Xylazine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylazine</td>
<td>ng/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

52135TI  Xylazine Confirmation, Tissue

Summary of Changes: Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylazine</td>
<td>ng/g</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

52135U  Xylazine Confirmation, Urine

Summary of Changes:
- Stability was changed.
- Units were changed.
- Methods/CPT Codes were changed [LC-MS/MS (80375)]

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylazine</td>
<td>ng/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

4815B  Xylazine, Blood

Summary of Changes:
- Specimen Requirements were changed.
- Specimen Requirements (Specimen Container) were changed.
- Stability was changed.
- Units were changed.
- Methods/CPT Codes were changed [LC-MS/MS (80375)]
Test Changes

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 2 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 7 day(s)
Scope of Analysis: LC-MS/MS (80375): Xylazine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylazine</td>
<td>ng/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

4815SP  Xylazine, Serum/Plasma

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Special Handling) were changed.
Stability was changed.
Units were changed.
Methods/CPT Codes were changed [LC-MS/MS (80375)]

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial
using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80375): Xylazine

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylazine</td>
<td>ng/mL</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>
### Test Changes

**Summary of Changes:**

- Units were changed.
- Methods/CPT Codes were changed [LC-MS/MS (80375)]

**Scope of Analysis:**

| Method (CPT Code) | LC-MS/MS (80375): Xylazine |

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Units</th>
<th>Reference Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xylazine</td>
<td>ng/g</td>
<td>No reference data available.</td>
</tr>
</tbody>
</table>

**Stability:**

- Room Temperature: 30 day(s)
- Refrigerated: 30 day(s)
- Frozen (-20 °C): 30 day(s)

**Scope of Analysis:**

| Method (CPT Code) | LC-MS/MS (80375): Xylazine |

**Summary of Changes:**

- Stability was changed.
- Methods/CPT Codes were changed [LC-MS/MS (80375)]
## Discontinued Tests

<table>
<thead>
<tr>
<th>Test Code</th>
<th>Test Name</th>
<th>Alternative Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>0213B</td>
<td>Allopurinol and Metabolite, Blood</td>
<td>0213SP - Allopurinol and Metabolite, Serum/Plasma</td>
</tr>
<tr>
<td>0982SP</td>
<td>Carbidopa, Serum/Plasma</td>
<td>0213SP - Allopurinol and Metabolite, Serum/Plasma</td>
</tr>
<tr>
<td>5498B</td>
<td>Dicyclomine Confirmation, Blood</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>9151B</td>
<td>Dicyclomine Screen, Blood</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>1902B</td>
<td>Duexis®, Blood</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>1902SP</td>
<td>Duexis®, Serum/Plasma</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>9323SP</td>
<td>Ethane, Serum/Plasma</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>2068SP</td>
<td>Famotidine, Serum/Plasma</td>
<td>2068B - Famotidine, Blood</td>
</tr>
<tr>
<td>2834B</td>
<td>Methanol, Blood</td>
<td>2835B - Methanol, Blood</td>
</tr>
<tr>
<td>2834SP</td>
<td>Methanol, Serum/Plasma</td>
<td>2835SP - Methanol, Serum/Plasma</td>
</tr>
<tr>
<td>2834U</td>
<td>Methanol, Urine</td>
<td>2835U - Methanol, Urine</td>
</tr>
<tr>
<td>52107FL</td>
<td>Procainamide and NAPA Confirmation, Fluid</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>52107TI</td>
<td>Procainamide and NAPA Confirmation, Tissue</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>3230B</td>
<td>Symbyax®, Blood</td>
<td>No Alternate Tests Available</td>
</tr>
<tr>
<td>3230SP</td>
<td>Symbyax®, Serum/Plasma</td>
<td>No Alternate Tests Available</td>
</tr>
</tbody>
</table>